Brokerages Set MoonLake Immunotherapeutics (NASDAQ:MLTX) PT at $81.43

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $81.43.

MLTX has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of MoonLake Immunotherapeutics in a research note on Monday, September 23rd. Wedbush reissued an "outperform" rating and issued a $73.00 target price (down from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. Finally, HC Wainwright reissued a "buy" rating and issued a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Friday.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MLTX. US Bancorp DE bought a new position in MoonLake Immunotherapeutics during the 3rd quarter worth about $44,000. Quarry LP boosted its position in shares of MoonLake Immunotherapeutics by 172.7% during the second quarter. Quarry LP now owns 3,000 shares of the company's stock worth $132,000 after buying an additional 1,900 shares during the period. Barclays PLC grew its holdings in shares of MoonLake Immunotherapeutics by 1,269.2% during the third quarter. Barclays PLC now owns 5,641 shares of the company's stock worth $283,000 after buying an additional 5,229 shares in the last quarter. Handelsbanken Fonder AB raised its position in MoonLake Immunotherapeutics by 26.2% in the 3rd quarter. Handelsbanken Fonder AB now owns 13,000 shares of the company's stock valued at $655,000 after buying an additional 2,700 shares during the last quarter. Finally, AlphaCentric Advisors LLC bought a new stake in MoonLake Immunotherapeutics in the 3rd quarter valued at approximately $706,000. Institutional investors and hedge funds own 93.85% of the company's stock.

MoonLake Immunotherapeutics Trading Down 3.9 %

Shares of MoonLake Immunotherapeutics stock traded down $1.86 on Friday, reaching $46.31. 451,482 shares of the company were exchanged, compared to its average volume of 467,630. MoonLake Immunotherapeutics has a fifty-two week low of $37.55 and a fifty-two week high of $64.98. The firm has a market capitalization of $2.96 billion, a price-to-earnings ratio of -35.90 and a beta of 1.31. The stock has a fifty day moving average price of $52.17 and a 200-day moving average price of $48.91.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.12). During the same quarter in the prior year, the firm earned ($0.18) EPS. On average, equities analysts anticipate that MoonLake Immunotherapeutics will post -1.75 earnings per share for the current fiscal year.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.